▁Introduction 7.8203125
: 1.90625
<0x0A> 6.52734375
In 3.412109375
▁a 3.435546875
▁notable 9.2890625
▁development 3.931640625
▁in 2.228515625
▁the 0.6806640625
▁fight 4.9765625
▁against 0.284912109375
▁cancer 5.15625
, 0.1417236328125
▁British 6.2734375
▁bi 3.849609375
ote 0.392822265625
ch 0.452880859375
▁firm 0.7109375
, 2.357421875
▁yet 15.578125
▁to 3.3515625
▁be 0.55078125
▁named 0.68310546875
, 0.1282958984375
▁has 0.8466796875
▁released 5.7890625
▁encourag 6.87109375
ing 0.0009517669677734375
▁early 2.87109375
- 2.482421875
stage 0.07086181640625
▁results 1.0419921875
▁for 1.625
▁a 0.92431640625
▁ground 4.7421875
bre 0.6455078125
aking 0.00021851062774658203
▁cancer 1.88671875
▁drug 2.041015625
. 0.95947265625
▁However 6.484375
, 0.0153961181640625
▁c 9.0234375
aut 0.6728515625
ious 0.02197265625
▁voices 5.31640625
▁in 2.75
▁the 0.07135009765625
▁industry 1.6123046875
▁are 1.4658203125
▁rem 4.67578125
inding 0.00792694091796875
▁us 1.3017578125
▁that 0.38330078125
▁further 5.52734375
▁tests 2.912109375
▁and 2.5078125
▁tri 1.294921875
als 0.0004489421844482422
▁are 0.4482421875
▁necessary 1.984375
▁before 0.77294921875
▁definit 6.05078125
ive 0.0401611328125
▁conclus 0.369873046875
ions 0.0006346702575683594
▁can 0.1500244140625
▁be 0.004398345947265625
▁drawn 0.685546875
. 0.18896484375
▁The 3.0234375
▁potential 4.76953125
▁of 1.25390625
▁this 0.7109375
▁drug 0.98388671875
▁to 1.466796875
▁provide 4.01171875
▁new 3.24609375
▁hope 0.65087890625
▁to 0.8916015625
▁cancer 0.78173828125
▁patients 0.2386474609375
▁makes 5.1015625
▁it 0.416748046875
▁an 1.169921875
▁exc 0.783203125
iting 4.088878631591797e-05
▁prospect 1.4716796875
, 0.85205078125
▁but 0.572265625
▁exper 4.84375
ts 0.00013196468353271484
▁are 1.021484375
▁ur 0.8935546875
ging 0.00047969818115234375
▁vig 6.1015625
il 0.0004425048828125
ance 0.0015010833740234375
▁and 1.0703125
▁careful 4.51953125
▁evaluation 2.1796875
▁before 0.92919921875
▁celebr 3.990234375
ating 0.157958984375
▁any 2.375
▁potential 2.826171875
▁break 0.431884765625
through 0.0002944469451904297
s 0.76611328125
. 0.145263671875
<0x0A> 0.26513671875
Body 9.7265625
: 0.12408447265625
<0x0A> 7.4453125
1 3.158203125
. 0.09759521484375
▁Ex 5.50390625
c 0.61962890625
iting 0.1016845703125
▁Promise 7.69921875
▁from 3.8046875
▁Initial 5.1015625
▁Tri 0.83251953125
als 0.1534423828125
: 0.73486328125
<0x0A> 0.431884765625
Acc 3.990234375
ording 0.0006194114685058594
▁to 0.0006108283996582031
▁the 1.2822265625
▁British 3.083984375
▁bi 0.169921875
ote 0.004405975341796875
ch 0.0132598876953125
▁company 2.080078125
, 0.23876953125
▁the 0.77587890625
▁pre 4.2734375
lim 0.173828125
inary 0.0001392364501953125
▁find 2.431640625
ings 2.0265579223632812e-05
▁from 0.71826171875
▁initial 4.2578125
▁clin 1.8525390625
ical 0.0003039836883544922
▁tri 0.037384033203125
als 4.220008850097656e-05
▁of 2.166015625
▁their 1.3310546875
▁innov 4.19140625
ative 0.0009121894836425781
▁cancer 0.441162109375
▁drug 0.262451171875
▁appear 5.125
▁to 0.68505859375
▁be 0.280517578125
▁highly 1.9580078125
▁prom 0.337158203125
ising 0.00023949146270751953
. 0.06085205078125
▁These 4.6015625
▁early 1.3203125
▁results 0.91015625
▁suggest 0.98876953125
▁that 0.07745361328125
▁the 0.09686279296875
▁drug 0.1207275390625
▁may 0.89794921875
▁have 1.58984375
▁the 0.87451171875
▁potential 0.0657958984375
▁to 0.0020122528076171875
▁significantly 1.1318359375
▁improve 0.55126953125
▁treatment 3.318359375
▁options 2.796875
▁for 0.08050537109375
▁a 2.86328125
▁range 1.232421875
▁of 0.00014889240264892578
▁cancer 1.1708984375
▁types 0.37060546875
▁by 5.10546875
▁target 1.0966796875
ing 0.00045371055603027344
▁specific 1.4013671875
▁signal 6.30078125
ing 0.02764892578125
▁path 0.07794189453125
ways 0.0008602142333984375
▁within 1.53515625
▁the 1.35546875
▁cells 2.2890625
, 4.1484375
▁in 4.18359375
hib 0.11962890625
iting 0.0016794204711914062
▁the 1.7412109375
▁growth 0.2421875
▁and 0.8056640625
▁spread 0.276611328125
▁of 0.003997802734375
▁cancer 1.130859375
ous 1.22265625
▁cells 1.5048828125
. 0.56201171875
▁If 5.5546875
▁successful 4.08203125
, 0.138916015625
▁this 0.42626953125
▁ground 4.33984375
bre 0.0335693359375
aking 2.8252601623535156e-05
▁medic 4.84765625
ation 0.0015726089477539062
▁could 0.164306640625
▁change 5.04296875
▁the 0.05108642578125
▁landscape 1.474609375
▁of 0.0159149169921875
▁cancer 0.06207275390625
▁treatment 0.1649169921875
. 2.69921875
<0x0A> 0.060821533203125
2 0.052642822265625
. 0.0050506591796875
▁Ca 1.57421875
ution 0.0218963623046875
ary 1.8720703125
▁Analysis 8.078125
: 1.6767578125
<0x0A> 0.016143798828125
Des 1.130859375
p 3.3855438232421875e-05
ite 1.4662742614746094e-05
▁the 0.5947265625
▁initial 2.126953125
▁excitement 1.8134765625
, 0.689453125
▁anal 6.1875
yst 0.005680084228515625
s 0.0010099411010742188
▁are 1.0703125
▁emphas 3.5625
izing 0.0225982666015625
▁the 0.7158203125
▁importance 0.88134765625
▁of 0.0015125274658203125
▁proceed 3.458984375
ing 0.0007686614990234375
▁with 0.31005859375
▁ca 0.0653076171875
ution 1.4424324035644531e-05
. 1.33984375
▁They 2.833984375
▁stress 3.021484375
▁the 2.021484375
▁need 0.1837158203125
▁for 0.06414794921875
▁further 0.50439453125
▁investig 5.65625
ations 0.024139404296875
, 2.947265625
▁including 1.625
▁additional 3.62109375
▁clin 0.50048828125
ical 0.00019979476928710938
▁tri 0.032501220703125
als 1.2636184692382812e-05
▁involving 3.685546875
▁larger 0.27392578125
▁patient 0.85302734375
▁coh 2.787109375
ort 1.7881393432617188e-06
s 0.0006303787231445312
, 0.7236328125
▁to 1.2197265625
▁assess 3.365234375
▁the 0.1585693359375
▁drug 0.97802734375
' 1.3544921875
s 0.0001322031021118164
▁safety 1.2275390625
▁and 0.25146484375
▁effic 0.2093505859375
acy 3.1828880310058594e-05
. 0.77783203125
▁Conc 8.2578125
ern 0.002685546875
s 0.031005859375
▁have 0.6494140625
▁also 0.7353515625
▁been 0.0182342529296875
▁raised 0.09661865234375
▁regarding 1.58984375
▁potential 1.6591796875
▁side 0.31494140625
▁effects 0.01399993896484375
▁and 1.1689453125
▁the 1.0712890625
▁drug 1.193359375
' 0.0180206298828125
s 6.222724914550781e-05
▁limitations 7.11328125
▁in 0.63427734375
▁tre 1.2939453125
ating 9.179115295410156e-06
▁specific 2.69140625
▁cancer 1.3916015625
▁stra 8.875
ins 0.000640869140625
. 0.089599609375
▁This 5.17578125
▁measured 9.6015625
▁response 3.14453125
▁serves 3.265625
▁as 0.1571044921875
▁a 0.0963134765625
▁rem 0.1688232421875
inder 1.895427703857422e-05
▁that 0.263427734375
▁medical 4.19921875
▁break 0.84423828125
through 1.430511474609375e-05
s 0.00041484832763671875
▁often 2.486328125
▁require 0.697265625
▁persistent 7.9765625
▁efforts 3.01171875
▁and 0.5771484375
▁met 3.7734375
icul 0.00011682510375976562
ous 0.0009598731994628906
▁scr 2.427734375
ut 1.1324882507324219e-05
iny 0.00323486328125
. 1.48828125
<0x0A> 0.018951416015625
3 0.2462158203125
. 0.002994537353515625
▁Address 7.0390625
ing 0.005954742431640625
▁Pot 2.869140625
ential 0.001926422119140625
▁Ch 2.4375
alleng 0.00012767314910888672
es 7.581710815429688e-05
: 0.0396728515625
<0x0A> 0.00295257568359375
Bi 5.37109375
ote 0.111083984375
chn 2.41015625
ology 0.02569580078125
▁exper 1.921875
ts 2.9802322387695312e-06
▁assert 5.8046875
▁that 0.056732177734375
▁the 1.4189453125
▁long 5.96484375
▁road 2.8671875
▁from 3.373046875
▁initial 1.4287109375
▁testing 3.501953125
▁to 0.08465576171875
▁successful 3.55078125
▁commercial 1.595703125
ization 0.0653076171875
▁is 0.99462890625
▁often 2.93359375
▁fra 0.9794921875
ug 1.0728836059570312e-06
ht 1.6689300537109375e-06
▁with 0.00092315673828125
▁challeng 1.1435546875
es 0.0012216567993164062
. 0.4775390625
▁These 1.6015625
▁hur 3.451171875
d 1.3113021850585938e-06
les 8.153915405273438e-05
▁include 1.1259765625
▁rig 4.99609375
orous 0.00988006591796875
▁regul 0.45263671875
atory 4.3511390686035156e-05
▁appro 0.7080078125
val 8.463859558105469e-06
s 2.28125
, 0.1259765625
▁scr 7.9765625
ut 0.00215911865234375
iny 0.182861328125
▁from 0.2919921875
▁the 1.8173828125
▁scientific 0.92626953125
▁community 0.04150390625
, 0.034759521484375
▁and 0.1458740234375
▁the 1.2451171875
▁need 1.0283203125
▁for 0.65478515625
▁substantial 3.291015625
▁invest 1.2587890625
ments 1.626953125
▁to 1.90625
▁support 1.837890625
▁compreh 6.421875
ensive 6.747245788574219e-05
▁clin 0.403564453125
ical 8.487701416015625e-05
▁tri 0.0628662109375
als 3.7550926208496094e-05
. 0.1370849609375
▁Furthermore 4.25390625
, 0.00011610984802246094
▁un 5.44140625
for 0.8037109375
ese 5.042552947998047e-05
en 0.00244140625
▁comp 1.9326171875
lications 0.0009717941284179688
▁can 1.4921875
▁arise 0.59912109375
▁during 0.5693359375
▁later 4.52734375
▁stages 0.332763671875
▁of 0.0467529296875
▁drug 1.9130859375
▁development 0.021636962890625
, 0.216064453125
▁prompt 4.51171875
ing 7.331371307373047e-05
▁the 2.26171875
▁need 0.165771484375
▁for 0.019989013671875
▁adjust 3.759765625
ments 0.027191162109375
▁or 1.3740234375
▁re 3.099609375
ass 1.92578125
ess 0.0014820098876953125
ment 0.8701171875
. 0.9873046875
▁Despite 1.876953125
▁the 2.943359375
▁enthus 6.6484375
ias 0.0273895263671875
m 2.968311309814453e-05
▁surrounding 0.689453125
▁the 1.6376953125
▁drug 3.1171875
' 0.2313232421875
s 8.630752563476562e-05
▁potential 1.365234375
, 0.1578369140625
▁industry 3.61328125
▁watch 3.271484375
ers 0.035125732421875
▁stress 3.244140625
▁that 1.1806640625
▁p 4.10546875
atience 0.12017822265625
, 2.380859375
▁dil 2.142578125
ig 0.0144195556640625
ence 3.9696693420410156e-05
, 0.01024627685546875
▁and 0.0009160041809082031
▁additional 8.796875
▁evidence 5.203125
▁are 0.330322265625
▁cru 1.98828125
cial 0.00010204315185546875
▁to 1.6572265625
▁adv 4.1796875
ancement 5.65234375
. 0.20556640625
<0x0A> 0.033843994140625
4 0.88916015625
. 0.0024280548095703125
▁Pot 3.169921875
ential 0.01043701171875
▁Imp 1.34765625
act 0.408203125
▁on 0.317138671875
▁Can 0.6142578125
cer 0.00016701221466064453
▁Tre 0.5673828125
at 8.20159912109375e-05
ment 0.037506103515625
: 0.043609619140625
<0x0A> 0.0014448165893554688
If 1.533203125
▁the 1.2109375
▁British 2.99609375
▁bi 0.024688720703125
ote 0.0018596649169921875
ch 0.058624267578125
▁firm 1.1708984375
' 0.1766357421875
s 3.0994415283203125e-05
▁cancer 2.58203125
▁drug 0.058258056640625
▁passes 4.2734375
▁further 2.7734375
▁rig 4.70703125
orous 0.0037746429443359375
▁testing 1.431640625
▁and 0.76953125
▁obtain 3.748046875
s 0.0009365081787109375
▁regul 0.33154296875
atory 0.00012087821960449219
▁appro 0.01253509521484375
val 3.421306610107422e-05
, 0.10125732421875
▁the 3.68359375
▁imp 0.998046875
lications 0.002323150634765625
▁for 0.73193359375
▁cancer 0.184326171875
▁treatment 0.431884765625
▁could 0.276611328125
▁be 0.007106781005859375
▁enorm 3.119140625
ous 0.0007939338684082031
. 0.00679779052734375
▁Research 4.96875
ers 0.18408203125
▁believe 1.6748046875
▁that 0.226318359375
▁specifically 8.71875
▁target 0.048919677734375
ed 1.9501953125
▁dru 1.806640625
gs 6.389617919921875e-05
▁have 2.8125
▁the 0.12408447265625
▁potential 0.05230712890625
▁not 7.69140625
▁only 0.03179931640625
▁to 0.002056121826171875
▁improve 0.95166015625
▁patients 3.548828125
' 0.01153564453125
▁ch 3.1484375
ances 1.4185905456542969e-05
▁for 4.078125
▁surv 0.70361328125
ival 0.007587432861328125
▁but 0.183837890625
▁also 0.040863037109375
▁to 0.09881591796875
▁minim 1.982421875
ize 0.0010824203491210938
▁har 6.20703125
sh 0.005527496337890625
▁side 0.09442138671875
▁effects 0.0034580230712890625
▁often 2.375
▁associated 0.1590576171875
▁with 0.00014507770538330078
▁conventional 1.3291015625
▁treat 1.5751953125
ments 2.205371856689453e-05
▁like 3.169921875
▁chem 0.0310211181640625
other 0.0033626556396484375
apy 0.00019919872283935547
▁and 1.033203125
▁radiation 0.2064208984375
▁ther 0.64306640625
apy 0.0011911392211914062
. 0.0097808837890625
▁Still 5.84375
, 0.0031280517578125
▁this 4.078125
▁new 3.662109375
▁drug 1.5224609375
▁must 2.06640625
▁be 2.45703125
▁subject 2.3203125
ed 0.11456298828125
▁to 0.0006995201110839844
▁extensive 1.923828125
▁research 3.67578125
, 3.1484375
▁clin 3.037109375
ical 0.0005545616149902344
▁tri 0.07574462890625
als 9.584426879882812e-05
, 0.01061248779296875
▁and 0.0137939453125
▁peer 5.484375
▁reviews 1.419921875
▁before 0.3046875
▁it 0.9375
▁can 0.08770751953125
▁real 6.57421875
ist 0.00982666015625
ically 2.2649765014648438e-06
▁be 0.82080078125
▁incorpor 4.25390625
ated 6.330013275146484e-05
▁into 0.018463134765625
▁standard 1.4921875
▁cancer 0.7451171875
▁treatment 1.6767578125
▁practices 2.890625
. 0.0703125
<0x0A> 0.110107421875
5 0.49365234375
. 0.004497528076171875
▁Indust 3.935546875
ry 0.002780914306640625
▁Imp 4.99609375
lications 0.2149658203125
: 0.086669921875
<0x0A> 0.0020885467529296875
The 0.697265625
▁success 3.421875
▁of 0.06842041015625
▁this 0.7333984375
▁British 2.74609375
▁bi 0.023040771484375
ote 0.001476287841796875
ch 0.055145263671875
▁firm 0.395751953125
' 0.0506591796875
s 5.3882598876953125e-05
▁drug 2.04296875
▁could 0.73486328125
▁significantly 2.400390625
▁impact 0.44921875
▁the 0.1463623046875
▁bi 2.150390625
ote 0.1021728515625
chn 0.297119140625
ology 0.0021419525146484375
▁and 2.435546875
▁ph 0.0975341796875
arma 0.0004794597625732422
ce 0.0011501312255859375
ut 1.3113021850585938e-06
ical 9.083747863769531e-05
▁indust 0.1378173828125
ries 5.4836273193359375e-06
▁at 6.2421875
▁large 0.037353515625
. 0.06640625
▁If 2.888671875
▁the 0.76904296875
▁drug 0.284912109375
▁proves 0.88525390625
▁successful 2.8671875
▁in 0.73291015625
▁later 3.2890625
▁stages 1.2119140625
▁of 0.0955810546875
▁development 1.1435546875
, 0.327880859375
▁it 0.332275390625
▁may 1.8515625
▁p 2.451171875
ave 0.0036411285400390625
▁the 0.004123687744140625
▁way 0.0023174285888671875
▁for 0.0018835067749023438
▁other 1.6572265625
▁similar 2.31640625
▁target 2.43359375
ed 0.00966644287109375
▁ther 0.86572265625
ap 0.00800323486328125
ies 4.5299530029296875e-06
▁to 1.59375
▁gain 4.41015625
▁cred 7.90625
ibility 0.09912109375
▁and 0.46044921875
▁invest 4.1875
or 2.80859375
▁interest 0.87109375
. 0.197021484375
▁This 1.6904296875
, 2.783203125
▁in 0.01104736328125
▁turn 0.0005059242248535156
, 0.0002162456512451172
▁could 0.1590576171875
▁lead 1.49609375
▁to 0.0006871223449707031
▁further 3.638671875
▁adv 1.240234375
anc 0.168701171875
ements 5.364418029785156e-06
▁in 0.10247802734375
▁tre 5.1953125
ating 2.193450927734375e-05
▁various 1.15625
▁dise 2.431640625
ases 3.039836883544922e-05
, 1.16796875
▁not 4.0859375
▁just 0.287841796875
▁cancer 0.059539794921875
. 0.2724609375
▁However 1.4638671875
, 0.00014650821685791016
▁with 5.07421875
▁the 1.7890625
▁potential 2.28125
▁for 0.310546875
▁immense 4.62890625
▁financial 1.6103515625
▁gain 1.9189453125
, 1.5595703125
▁anal 5.9453125
yst 0.00026726722717285156
s 0.00012874603271484375
▁warn 1.1171875
▁against 1.40625
▁hast 3.205078125
y 0.2384033203125
▁conclus 1.1142578125
ions 0.0001176595687866211
▁or 2.2421875
▁infl 5.171875
ated 0.00948333740234375
▁expect 0.33740234375
ations 2.562999725341797e-05
, 1.75
▁stress 2.623046875
ing 4.6372413635253906e-05
▁the 0.45654296875
▁importance 0.78271484375
▁of 0.0003571510314941406
▁maintain 3.171875
ing 0.00014281272888183594
▁object 3.740234375
ivity 0.0009312629699707031
▁and 0.226318359375
▁prior 4.1953125
it 0.0004527568817138672
izing 0.000965118408203125
▁patient 0.5869140625
▁safety 0.37109375
▁and 2.880859375
▁well 0.7802734375
- 0.1085205078125
be 0.0003390312194824219
ing 3.731250762939453e-05
. 0.392578125
<0x0A> 0.06732177734375
Con 1.8798828125
clusion 0.027923583984375
: 0.03814697265625
<0x0A> 7.41796875
As 2.306640625
▁British 3.990234375
▁bi 0.0214385986328125
ote 0.0008602142333984375
ch 0.0777587890625
▁research 4.24609375
ers 0.141357421875
▁report 5.95703125
▁prom 0.64599609375
ising 3.0875205993652344e-05
▁results 1.2626953125
▁in 2.849609375
▁early 0.994140625
- 0.998046875
stage 0.012786865234375
▁tri 0.833984375
als 7.283687591552734e-05
▁for 1.064453125
▁a 0.5732421875
▁ground 2.076171875
bre 0.01300048828125
aking 1.6570091247558594e-05
▁cancer 0.11383056640625
▁drug 0.090087890625
, 0.01393890380859375
▁industry 2.1953125
▁exper 0.7958984375
ts 9.059906005859375e-06
▁and 3.51953125
▁anal 1.8935546875
yst 0.00011992454528808594
s 0.00010955333709716797
▁ins 7.36328125
ist 0.0004487037658691406
▁on 0.408447265625
▁maintain 3.65234375
ing 0.00010836124420166016
▁a 0.556640625
▁level 2.994140625
- 0.92529296875
head 0.0003285408020019531
ed 0.0027179718017578125
▁approach 0.810546875
. 0.408447265625
▁Though 3.787109375
▁the 0.95068359375
▁potential 1.1708984375
▁to 3.50390625
▁revolution 1.2861328125
ize 0.00150299072265625
▁cancer 0.1796875
▁treatment 0.0736083984375
▁is 0.1683349609375
▁und 1.8251953125
ou 1.626953125
bt 0.0003097057342529297
edly 0.001495361328125
▁exc 0.469970703125
iting 2.6226043701171875e-06
, 0.0264434814453125
▁ca 1.88671875
ution 0.003627777099609375
▁prev 8.515625
ails 0.00012600421905517578
. 2.70703125
▁R 4.69140625
ig 0.01548004150390625
orous 0.003314971923828125
▁testing 1.052734375
, 0.7431640625
▁repeat 11.0390625
able 0.58935546875
▁results 0.74072265625
, 0.021759033203125
▁and 0.06146240234375
▁extensive 3.044921875
▁tri 5.15625
als 0.0018367767333984375
▁are 0.751953125
▁necessary 0.5966796875
▁to 0.9326171875
▁confirm 2.55078125
▁the 0.3701171875
▁drug 0.274169921875
' 0.00438690185546875
s 6.0677528381347656e-05
▁effic 0.72900390625
acy 2.8252601623535156e-05
▁and 0.200439453125
▁safety 0.3046875
▁before 1.7470703125
▁it 0.654296875
▁can 0.09075927734375
▁become 2.064453125
▁a 0.381103515625
▁vi 0.6201171875
able 6.556510925292969e-06
▁treatment 0.92919921875
▁option 0.014007568359375
. 0.61328125
▁While 2.671875
▁optim 3.640625
ism 0.04901123046875
▁is 1.025390625
▁encourag 2.9140625
ed 0.01358795166015625
, 0.04241943359375
▁it 2.314453125
▁is 0.54736328125
▁inc 5.9609375
umb 2.3126602172851562e-05
ent 1.6570091247558594e-05
▁upon 0.1846923828125
▁everyone 3.630859375
▁involved 0.336669921875
▁to 0.5263671875
▁temper 5.578125
▁expect 1.57421875
ations 0.00021457672119140625
, 2.638671875
▁ens 5.3125
uring 0.0001157522201538086
▁that 0.2481689453125
▁patient 2.029296875
▁well 1.546875
- 0.0821533203125
be 0.00011086463928222656
ing 0.0006389617919921875
▁remains 0.1954345703125
▁the 0.51220703125
▁driving 4.921875
▁force 0.0537109375
▁behind 0.19580078125
▁these 3.9609375
▁scientific 3.8671875
▁adv 0.53515625
anc 0.07659912109375
ements 1.3113021850585938e-05
. 0.016265869140625
